Tislelizumab and radiation before surgery for head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests whether giving a combination of immunotherapy (tislelizumab) and focused radiation therapy (SBRT) before surgery can help treat head and neck squamous cell carcinoma that is advanced but can still be removed. The goal is to see if this approach works better than standard treatment alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a newly diagnosed, surgically removable type of head and neck cancer called squamous cell carcinoma.
- Your cancer is stage III to IVB (except HPV-positive oropharyngeal cancer).
- A team of doctors has confirmed your tumor can be removed with surgery, possibly after radiation.
- You are between 18 and 70 years old.
- You are generally active and able to care for yourself (Karnofsky score 70 or higher).
- Your major organs (heart, lungs, liver, kidneys) are working well enough for the treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (tirelizumab, carboplatin, and a special form of paclitaxel) given before surgery to treat advanced head and neck cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.
This trial tests whether giving tislelizumab (an immunotherapy) with chemotherapy before surgery works better than surgery alone for people with head and neck cancer that has not spread to lymph nodes. It's for cancers that can be removed with surgery, and the goal is to see if the pre-surgery treatment improves outcomes.
This Phase 2 study tests whether giving low-dose radiation before surgery—along with chemotherapy and an immunotherapy drug—can work better and be safe for treating locally advanced head and neck squamous cell cancer. It may help shrink tumors before surgery and reduce the chance of the cancer coming back.
This trial tests whether combining radiation therapy with immunotherapy works better than immunotherapy alone for advanced head and neck cancer that hasn't been treated before. The goal is to help your body's immune system fight the cancer more effectively.
This Phase 2 trial tests tirelizumab combined with two chemotherapy medicines before surgery for certain head and neck squamous cell cancers. It aims to shrink the tumor and improve outcomes after the operation.
This trial tests whether giving the immunotherapy drug tislelizumab with chemotherapy before surgery can help people with advanced head and neck cancer. The goal is to shrink the tumor enough to remove it completely during surgery.
Hear when a new HNSCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.